Now

Ancient & Auctioned: Egyptian Piece Sold For £10,000

Published

2 years ago

October 31, 2018

Sotheby’s International Auction House in London presented an auction titled “The Arts of the Islamic World in the Middle East”. The auction included four Egyptian manuscripts for sale.

Only one Egyptian manuscript was sold, which is a great binding for Morocco, Egypt and Syria, that goes back to the 15th century, dating back to the Mamluks era. The piece was valued at £10,000.

There are three remaining Egyptian manuscripts were not held for sale in the auction, and included one which dates back to the Mamluks era during the 14th and early 15th centuries. The piece was labeled “Al-Samad Astrological Images” and was valued at an estimate cost of £6,000 to 8,000, while the third manuscript is a text from the Holy Quran, dating back to the second half of the 14th century, and is estimated to cost between £6,000 and 8,000.

The fourth manuscript is part of the 14th century Quran scripts, estimated at a value of £8,000 to 12,000.

Now

AstraZeneca COVID-19 vaccine Shows 90% Effectiveness With No Serious Side Effects

Published

2 weeks ago

November 23, 2020

Yara K

AstraZeneca announced today the effectiveness of its Covid-19 vaccine and it turned out to be around 90% effective with no serious side effects!

According to data from the late-stage trials in Britain and Brazil, the vaccine, which is developed by Oxford University, has shown 90% effectiveness after being administered as a a half dose followed by a full dose at least one month apart.

“This vaccine’s efficacy and safety confirm that it will be highly effective against COVID-19 and will have an immediate impact on this public health emergency,” Pascal Soriot, Astra’s chief executive, said in a statement.

British Prime minister Boris Johnson said it was “incredibly exciting news the Oxford vaccine has proved so effective in trials.”

The next step now is for the company to start preparing regulatory submission of the data to authorities across the world that have a framework in place for conditional or early approval.

It will also seek an emergency use listing from the World Health Organization (WHO) to speed up availability in countries with low income. In parallel, the full analysis of the interim results is being submitted for publication in a peer-reviewed journal.

With both Oxford’s and Pfizer’s vaccines, we can be hopeful that the new year will come bearing good news!

Now

Another Coronavirus Vaccine By Moderna Shows 94.5% Effectiveness!

Published

3 weeks ago

November 16, 2020

Yara K

Yet another promising news for a Covid-19 vaccine has been announced! Moderna said today that its vaccine has shown 94.5% effectiveness in preventing the virus, according to an analysis of its clinical trial.

The biotech company made the announcement earlier today, giving us a dash of hope amidst this coronavirus scare.

The news follows the announcement made by Pfizer and BioNTech, who said their vaccine was more than 90% effective.

The results come from interim analyses of intensive clinical studies. The clinical trials of Moderna saw the participation of 30,000 volunteers. Half got two doses of the vaccine 28 days apart, half got two shots of a placebo on the same schedule.

“This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease,” said Stéphane Bancel, chief executive officer of Moderna, in a statement.

Both companies used the same technology in making the vaccines, which is a tech based on a molecule known as mRNA, or messenger RNA. That molecule contains genetic instructions for making proteins inside cells.

We hope that by the end of this year, we can rest assured that a vaccine can soon end this pandemic.

Now

Hopes Rise As Pfizer Announces That Its COVID-19 Vaccine is 90% Effective

Published

4 weeks ago

November 10, 2020

Yara K

Hope rises as pharmaceutical giant Pfizer announced that its COVID-19 vaccine has successfully prevented 90% of the virus, a promising result that exceeded experts’ expectations!

This analysis is based on 94 cases of infection with SARS-CoV-2, the virus responsible for causing COVID-19, among both the vaccinated and placebo groups. The results included data from 38,955 of the total 43,538 volunteers who enrolled.

This makes Pfizer the very first company to release results from its Covid-19 vaccine, these findings are a result of collected seven days after the second of Pfizer’s two-shot regimen.